Banyu President Quits; Merck VP To Serve As Interim Boss (Japan)
This article was originally published in PharmAsia News
Executive SummaryBanyu Pharmaceutical Co. President Haruhiko Hirate will step down on Sept. 30. David Anstice, executive vice president of the firm's U.S. parent Merck & Co., will take over as interim chief until Hirate's successor is chosen. Hirate took office in January 2004 and, due partly to a lack of new products, failed to increase earnings. Sales totaled less than 200 billion yen in fiscal 2006, well below the target of more than 300 billion yen Hirate had set when he took over as president. (Click here for more - May Require Paid Subscription
You may also be interested in...
An experienced hand at M&A, Ajay Piramal has done it again – this time selling Decision Resources Group to Clarivate Analytics for $950m. Apart from $900m in cash, Piramal Enterprises will get a stake in Clarivate while the latter expects the acquisition to be earnings-accretive in 2020.
San Francisco-based digital health start-up Steady Health has launched the first "virtual" full-service diabetes clinic for patients in California. See what Henrik Berggren, CEO and founder of Steady Health, said about it here.
The first phase of a major trade agreement just signed by the US and China obliges the latter to implement a system linking pharma patent enforcement to marketing authorization procedures as well as to offer patent-term extensions.